Stereotaxis Announces Record Date for Rights Offering

Stereotaxis Announces Record Date for Rights Offering

ST. LOUIS, Oct. 29, 2013 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (Nasdaq:STXS)
announced today that it has fixed 5:00 p.m. New York City time on October 31,
2013 as the record date for determination of stockholders (and eligible
warrant holders) entitled to participate in its previously-announced rights
offering. Upon commencement of the rights offering, Stereotaxis will
distribute, at no charge to the holders of record of its common stock (and of
certain of its warrants), as of the record date referenced above, subscription
rights for each share of common stock (or warrant, as applicable) owned on the
record date. Each subscription right will entitle the holder to purchase
one-third of a share of common stock, at a price of $3.00 per share.

The subscription rights will be exercisable until 5:00 p.m. New York City
time, on November 21, 2013. Stereotaxis may, subject to certain limitations,
extend the rights offering, but does not currently intend to do so. Any
fractional rights remaining after aggregating all of the subscription rights
issued to shareholders and participating warrant holders will be rounded down
to the nearest whole number, and no shareholder or participating warrant
holder will receive any shares with respect to fractional rights that are
rounded down.

The rights will be listed on the NASDAQ Capital Market under the symbol
"STXSR," commencing on or about Friday, November 1, 2013 and continuing
through the expiration of the rights offering. The ex-rights date for the
rights offering is pending and will be announced once it is established by
NASDAQ. The ex-rights date is the date on which Stereotaxis's common stock
will begin to trade without the subscription rights and the rights will trade
separately from the common stock. As a result, shareholders who sell their
shares prior to the ex-rights date will also be selling their subscription

This press release does not constitute an offer to sell or the solicitation of
an offer to buy nor will there be any sale of any securities referred to in
this press release in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or qualification
under the securities laws of such state or jurisdiction. A registration
statement relating to the rights was filed with the Securities and Exchange
Commission and was declared effective on October 29, 2013. The rights offering
is being made only by means of a prospectus filed by the Company with the
Securities and Exchange Commission on October 29, 2013. Copies of the
prospectus, which will contain further details regarding the rights offering
will be provided to all stockholders and participating warrant holders as of
the record date.

A copy of the prospectus, or further information with respect to the rights
offering, may be obtained by calling the rights agent, Broadridge Corporate
Issuer Solutions, Inc., at (855) 300-4994.

About Stereotaxis

Stereotaxis is a healthcare technology and innovation leader in the
development of robotic cardiology instrument navigation systems designed to
enhance the treatment of arrhythmias and coronary disease, as well as
information management solutions for the interventional lab. With over 100
patents for use in a hospital's interventional surgical suite, Stereotaxis
helps physicians around the world provide unsurpassed patient care with
robotic precision and safety, improved lab efficiency and productivity, and
enhanced collaboration of life-saving information. Stereotaxis' core Epoch™
Solution includes the Niobe® ES Remote Magnetic Navigation system, the
Odyssey® portfolio of lab optimization, networking and patient information
management systems and the Vdrive™ Robotic Mechanical Navigation system and

The core components of Stereotaxis systems have received regulatory clearance
in the U.S., Europe, Canada and elsewhere. The V-Sono™ ICE catheter
manipulator has received U.S. clearance, and the V-Loop™ circular catheter
manipulator is currently in clinical trials in order to obtain clearance by
the U.S. Food and Drug Administration. For more information, please visit

This press release includes statements that may constitute "forward-looking"
statements, usually containing the words "believe," "estimate," "project,"
"expect" or similar expressions. Forward-looking statements inherently involve
risks and uncertainties that could cause actual results to differ materially
from the forward-looking statements. Factors that would cause or contribute to
such differences include, but are not limited to, the Company's ability to
raise additional capital or otherwise address ongoing liquidity challenges on
a timely basis and on terms that are acceptable, its ability to continue to
manage expenses and cash burn rate at sustainable levels, its ability to
continue to work with lenders to extend, repay or refinance indebtedness on
acceptable terms or at all, continued acceptance of the Company's products in
the marketplace, the effect of global economic conditions on the ability and
willingness of customers to purchase its systems and the timing of such
purchases, the outcome of various shareholder litigation filed against
Stereotaxis, competitive factors, changes resulting from the recently enacted
healthcare reform in the U.S., including changes in government reimbursement
procedures, dependence upon third-party vendors, timing of regulatory
approvals, and other risks discussed in the Company's periodic and other
filings with the Securities and Exchange Commission. By making these
forward-looking statements, the Company undertakes no obligation to update
these statements for revisions or changes after the date of this release.
There can be no assurance that the Company will recognize revenue related to
its purchase orders and other commitments in any particular period or at all
because some of these purchase orders and other commitments are subject to
contingencies that are outside of the Company's control. In addition, these
orders and commitments may be revised, modified, delayed or canceled, either
by their express terms, as a result of negotiations, or by overall project
changes or delays.

CONTACT: Company Contact:
         Marty Stammer
         Chief Financial Officer
         Investor Contact:
         Todd Kehrli / Jim Byers
         MKR Group, Inc.
Press spacebar to pause and continue. Press esc to stop.